A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: April 5, 2002
Last updated: February 8, 2007
Last verified: August 2003
The purpose of this study is to examine behavioral treatment for methamphetamine dependence.
Behavioral: Behavior Therapy
||Primary Purpose: Treatment
||Behavioral Trial for the Treatment of Methamphetamine Dependence
Primary Outcome Measures:
- Withdrawal symptoms
- New Use algorithm
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.
Additional criteria available during screening at the site.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033124
|South Bay Treatment Center
|Chula Vista, California, United States, 91911 |
|Matrix Institute on Addictions
|Costa Mesa, California, United States, 92627 |
|John A. Burns School of Medicine
|Honolulu, Hawaii, United States, 96813 |
|Powell Chemical Dependency Center
|Des Moines, Iowa, United States, 50316 |
|Comprehensive Mental Health Services, Inc
|Independence, Missouri, United States, 64052 |
||Richard Rawson, Ph.D.
||National Institute on Drug Abuse (NIDA)
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 5, 2002
||February 8, 2007
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Adrenergic Uptake Inhibitors
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs